Key facts
- Hale Animal Health’s last known valuation is $11.3M (Jan 2026).
- It has raised $4.4M; the latest was Early Stage VC ($2.3M) in Jan 2026.
- Notable investors include Enterprise Angels, Arrow Ventures, WNT Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Hale Animal Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Hale Animal Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hale Animal Health
Provider of veterinary pharmaceutical products intended to improve the quality of life of companion animals through science-led innovation and clinical research. The company offers clinically researched and regulator approved cannabinoid based therapies and an advancing pipeline of evidence-based medicines, enabling veterinarians and pet owners to address unmet needs in animal health with a strong focus on safety, well-being, and therapeutic effectiveness.
- Sector
- Healthcare
- HQ
- Auckland, New Zealand
- Founded
- 2020
- Employees
- 5
- Website
- haleanimal.co.nz/
- Ownership
- Privately Held (backing)
Hale Animal Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hale Animal Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hale Animal Health in its N-PORT filings yet. We sweep new filings monthly.